June 2019 - Volume 3 - Issue - Contributor Index

Author:
Eastburn, D.

THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML: S833

Morita, K.; Wang, F.; Jahn, K.; More

HemaSphere. 3:370, June 2019.

Author:
Eathiraj, S.
Author:
Ebeid, F.
Author:
Ebeling, F.
Author:
Ebina, T.
Author:
Ebrahim, F.
Author:
Eccersley, L.

INDIVIDUALIZED FOLLOW-UP IN ADULT ACUTE MYELOID LEUKEMIA USING NGS: PS1009

Iturri, Blasco Z.; Vazquez, I.; Ariceta, B.; More

HemaSphere. 3:453-454, June 2019.

Author:
Eckert, C.
Author:
Eclache, V.

B-CELL PROLYMPHOCYTIC LEUKEMIA (B-PLL) AND PROLYMPHOCYTOID MANTLE CELL LYMPHOMA (PMCL) (MORE THAN 55% OF PROLYMPHOCYTES) ARE CLOSED BUT DISTINCT ENTITIES. ON BEHALF GFCH AND FILO GROUPS: PB1868

Chapiro, E.; Diop, K.; Dessen, P.; More

HemaSphere. 3:851-852, June 2019.

Author:
Economou, M.
Author:
Ector, G.
Author:
Edahiro, Y.
Author:
eddhib, J.
Author:
Edenfield, W.
Author:
Eder, T.
Author:
Edesa, W.
Author:
Edwards, K.
Author:
Eek, D.
Author:
Efebera, Y. A.

ANCHOR (OP-104): A PHASE 1 STUDY UPDATE OF MELFLUFEN AND DEXAMETHASONE PLUS BORTEZOMIB OR DARATUMUMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS REFRACTORY TO AN IMID OR A PROTEASOME INHIBITOR: PF608

Pour, L.; Efebera, Y. A.; Granell, M.; More

HemaSphere. 3:257-258, June 2019.

Author:
Efeyan, A.
Author:
Efficace, F.

OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY: S882

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3:396-397, June 2019.

Author:
Efimov, G.

CMV-SPECIFIC T-CELL RECONSTITUTION AS A KEY FACTOR FOR IDENTIFICATION OF CANDIDATES FOR CMV-SPECIFIC LYMPHOCYTES INFUSION: PB2328

Dmitrova, A.; Shmarov, V.; Drokov, M.; More

HemaSphere. 3:1037, June 2019.

Author:
Efira, A.
Author:
Efobi, C.
Author:
Efremova, E.

PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE: PS1089

Vassilakopoulos, T.; Chatzidimitriou, C.; Mellios, Z.; More

HemaSphere. 3:494, June 2019.

Author:
Egle, A.

QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION: PS1509

Ludwig, H.; Pönisch, W.; Knop, S.; More

HemaSphere. 3:695-696, June 2019.

Author:
Egorova, E.

EPIDEMIOLOGICAL STUDY OF IDIOPATHIC THROMBOCYTOPENIC PURPURA AMONG THE ADULT POPULATION OF THE RUSSIAN FEDERATION: PS1104

Melikyan, A.; Egorova, E.; Pustovaya, E.; More

HemaSphere. 3:500, June 2019.

Author:
Egyed, M.

LONG TERM FOLLOW-UP OF PNH PATIENTS TREATED WITH THE SMART ANTI-HC5 ANTIBODY (SKY59/RO7112689) IN THE OPEN LABEL EXTENSION (OLE) OF THE COMPOSER TRIAL: PF348

Röth, A.; Nagy, Z.; de Latour, Peffault R.; More

HemaSphere. 3:125-126, June 2019.

MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI®) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS): PS1457

Gisslinger, H.; Klade, C.; Georgiev, P.; More

HemaSphere. 3:670-671, June 2019.

Author:
Ehara, H.
Author:
Ehinger, M.
Author:
Ehninger, G.

RATIFY: PROGNOSTIC IMPACT OF FLT3 TYROSINE KINASE DOMAIN (TKD) AND NPM1 MUTATION STATUS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) TREATED WITH MIDOSTAURIN + STANDARD CHEMOTHERAPY: PF256

Voso, M. T.; Larson, R. A.; Prior, T.; More

HemaSphere. 3:79-80, June 2019.

PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY: PF260

Döhner, K.; Thiede, C.; Jahn, N.; More

HemaSphere. 3:81-82, June 2019.

GENETIC LANDSCAPE OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITHIN THE RATIFY TRIAL: CALGB 10603 (ALLIANCE): PS968

Jahn, N.; Panina, E.; Bullinger, L.; More

HemaSphere. 3:436, June 2019.

CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA: S1614

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3:744-745, June 2019.

Author:
Ehrenfeld, S.
Author:
Eich, H.
Author:
Eichenauer, D.

EVEROLIMUS WITH DHAP (DEXAMETHASONE, HIGH-DOSE ARAC, CISPLATINUM) IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A RANDOMIZED, PLACEBO-CONTROLLED PHASE I/II TRIAL (HD-R3I): PS1240

von Tresckow, B.; Hüttmann, A.; Vucinic, V.; More

HemaSphere. 3:565, June 2019.

Author:
Eichhorst, B.

GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY: S105

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3:4, June 2019.

HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL: S106

Al-Sawaf, O.; Lilienweiss, E.; Bahlo, J.; More

HemaSphere. 3:4-5, June 2019.

FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES: S149

Fischer, K.; Al-Sawaf, O.; Bahlo, J.; More

HemaSphere. 3:26-27, June 2019.

FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY: PF381

Rhodes, J.; Sail, K.; Yazdy, Sarraf M.; More

HemaSphere. 3:142, June 2019.

IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY: PS1123

Wu, J.; Bolen, C.; Seymour, J. F.; More

HemaSphere. 3:508-509, June 2019.

Author:
Eichinger, S.
Author:
Eidelman, L. A.
Author:
Einsele, H.

EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY: S825

Topp, M.; Duell, J.; Zugmaier, G.; More

HemaSphere. 3:365, June 2019.

HACE1, A NOVEL TUMOR SUPPRESSOR GENE WHICH REGULATE THE RESPONSE OF VENETOCLAX, GANT61 AND NECROPTOSIS ACTIVATORS BY CONTROLLING C-FLIP, GLI2 AND BCL2 GENES IN ACUTE MYELOID LEUKEMIA: PS1001

Garitano, A.; Teufel, E.; Kreckel, J.; More

HemaSphere. 3:450, June 2019.

QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA-THAL-DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION: PS1509

Ludwig, H.; Pönisch, W.; Knop, S.; More

HemaSphere. 3:695-696, June 2019.

Author:
Eisa, N.
Author:
Eischer, L.
Author:
Eisele, F.
Author:
Eisen, M.

IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY: PS1377

Roussel, M.; Moreau, P.; Attal, M.; More

HemaSphere. 3:630, June 2019.

Author:
Eisfeld, A.-K.
Author:
Eissmann, P.
Author:
Eiznhamer, D.
Author:
ejiofor, O.
Author:
Ekaterina, P.

PROGNOSTIC AND PREDICTIVE IMPACT OF NPM1/FLT3-ITD GENOTYPES AS DEFINED BY 2017 EUROPEAN LEUKEMIANET RISK CATEGORIZATION FROM AML PATIENTS TREATED WITHIN THE INTERNATIONAL RATIFY STUDY: PF260

Döhner, K.; Thiede, C.; Jahn, N.; More

HemaSphere. 3:81-82, June 2019.

Author:
Eksmond, U.
Author:
Ekushov, K.

EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP: PS1077

Wudhikarn, K.; Bunworasate, U.; Julamanee, J.; More

HemaSphere. 3:488, June 2019.

Author:
El Ashkar, S.
Author:
El Ashwah, S.
Author:
El Beshlawy, A.

RESULTS FROM THE RANDOMIZED PLACEBO-CONTROLLED PHASE 3 HOPE TRIAL OF VOXELOTOR IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE: S147

Vichinsky, E.; Hoppe, C. C.; Ataga, K. I.; More

HemaSphere. 3:25-26, June 2019.

Author:
El Chazli, Y.
Author:
El Farra, A.
Author:
el Fassi, D.

THREE-YEAR ANALYSIS OF THE DALIAH TRIAL - A RANDOMIZED CONTROLLED PHASE III CLINICAL TRIAL COMPARING RECOMBINANT INTERFERON ALPHA-2 VS. HYDROXYUREA IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: S1609

Knudsen, T. A.; Hansen, Lund D.; Ocias, Frans L.; More

HemaSphere. 3:741-742, June 2019.

IMPACT OF SMOKING ON JAK2V617F ALLELE BURDEN AMONG PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS TREATED WITH PEGYLATED INTERFERON ALPHA-2 OR HYDROXYUREA IN THE DALIAH TRIAL: PB2210

Patel, D.; Knudsen, Alma T.; Hansen, Lund D.; More

HemaSphere. 3:990-991, June 2019.

Author:
El Fatmi, R.
Author:
El Gammal, M.
Author:
El Ghandour, A.

RESULTS FROM THE RANDOMIZED PLACEBO-CONTROLLED PHASE 3 HOPE TRIAL OF VOXELOTOR IN ADULTS AND ADOLESCENTS WITH SICKLE CELL DISEASE: S147

Vichinsky, E.; Hoppe, C. C.; Ataga, K. I.; More

HemaSphere. 3:25-26, June 2019.

Author:
El Halawany, N.
Author:
El Kenaai, N.
Show: